EugenieS.KleinermanMD
Pediatrics • Houston, TXAdolescent Medicine
Professor of Pediatrics, University Tex Houston
Dr. Kleinerman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Education & Training
Children's National HospitalResidency, Pediatrics, 1975 - 1978
Duke University School of MedicineClass of 1975
Certifications & Licensure
MD State Medical License 1978 - 2026
TX State Medical License 1984 - 2026- American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- Top Doctors:SE Texas Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2008-2013
- Join now to see all
Clinical Trials
- Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients Start of enrollment: 1997 Nov 01
- Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma Start of enrollment: 1996 Nov 01
Publications & Presentations
PubMed
- 124 citationsAnti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases.Pooja Dhupkar, Nancy Gordon, John Stewart, Eugenie S. Kleinerman
Cancer Medicine. 2018-06-01 - 89 citationsAnthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and PreventionAnchit Bhagat, Eugenie S. Kleinerman
Advances in Experimental Medicine and Biology. 2020-01-01 - 81 citationsAntagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungsEmmanuelle Pradelli, Babou Karimdjee-Soilihi, Michiels Jf, Jean-Ehrland Ricci, Marie Ange Millet
International Journal of Cancer. 2009-12-01
Press Mentions
Developing New Tools to Fight CancerOctober 17th, 2022
Straight to the Lungs: Inhaled Chemo Lessens Collateral DamageJune 11th, 2019
Program Spotlight: University of Puerto Rico and MD Anderson Partnership Welcomes Its First Graduates, Dedicated to Researching Cancer Health DisparitiesOctober 1st, 2014- Join now to see all
Grant Support
- Vasculogenesis In Ewing'S Sarcoma: Implications For TherapyNational Cancer Institute2008–2011
- Liposome And Polycationic Gene Therapy For OsteosarcomaNational Cancer Institute2000–2010
- Vasculogenesis In Ewing'S Sarcoma: Implications For TherapyNational Cancer Institute2007
- Vasculogenesis In Ewing'S Sarcoma: UseintherapyNational Cancer Institute2005–2006
- Vacdxr With Or Without Immther For Newly Diagnosed High Risk Ewing'S SarcomaNational Center For Research Resources2005
- Vacdxr With Or Without Immther For Ewing'S SarcomaNational Center For Research Resources2004
- Vasculogenesis In Ewing'S Sarcoma: Implications For TherNational Cancer Institute2004
- Vacdxr W/ Or W/Out Immther For Newly Diagnosed High Risk Ewings SarcomaNational Center For Research Resources2000–2002
- Chemo/Immunotherapy For High Risk Ewings SarcomaNational Cancer Institute1999–2001
- Vacdxr W/ Or W/Out Immther For Diagnosed High Risk Ewings SarcomaNational Center For Research Resources1999
- Liposome Therapy--A Potential Adjuvant For OsteosarcomaNational Cancer Institute1990–1999
- Efficacy Of IL1 And Etoposide In Relapsed OsteosarcomaNational Cancer Institute1995
- Liposome Therapy--A Potential Adjuvant For ChildhoodNational Cancer Institute1986–1989
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
